Invention Grant
- Patent Title: 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors
-
Application No.: US15574947Application Date: 2016-05-19
-
Publication No.: US10246447B2Publication Date: 2019-04-02
- Inventor: Anne Marie Jeanne Bouillot , Alexis Denis , John Liddle , Olivier Mirguet , Ann Louise Walker
- Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
- Applicant Address: GB Brentford, Middlesex
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Brentford, Middlesex
- Agent Grace C. Hsu; Fang Qian
- Priority: GB1508864.4 20150522
- International Application: PCT/EP2016/061173 WO 20160519
- International Announcement: WO2016/188827 WO 20161201
- Main IPC: C07D413/12
- IPC: C07D413/12

Abstract:
Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or ═O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.
Public/Granted literature
Information query